Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Adjunctive Probiotic Therapy in Major Depressive Disorder (ProMOOD)

A double-blind, randomized controlled trial (RCT) aimed at evaluating the efficacy of probiotic supplementation in patients undergoing concurrent antidepressant therapy. The study will also assess gut microbiome composition and function, and correlate microbiome changes with clinical and psychological outcomes. Participants will be evaluated by a psychiatrist/clinician, alongside standardized psychological assessments at: * Baseline (inclusion) * Week 4 * Week 12 The following validated instruments will be used: * HAM-D - Hamilton Depression Rating Scale (clinician-rated depression severity) * BDI - Beck Depression Inventory (self-reported severity of depression) * PSS - Perceived Stress Scale (self-reported stress perception) Inclusion Criteria * Age 18-65 years * Confirmed diagnosis of depression according to ICD 11 (International Classification of Diseases) criteria * Written informed consent * Stable antidepressant therapy (same medication for at least 6 weeks to ensure stable clinical response) Exclusion Criteria * Acute suicidality * Severe cardiovascular disease * Pregnancy or breastfeeding * Substance/ alcohol abuse * Severe neurological or systemic disease * Recent antibiotic use * Probiotic use in past year * Treatment resistant depression * Psychotic depression Sample Size * Initial recruitment target: 150-200 participants * Expected dropout rate: approximately 50%, based on similar studies * Final expected sample size: \~100 participants * Sample size calculation based on Nikolova et al., 2023. Primary outcome Change in Hamilton Depression Rating Scale (HAM-D-17) score from baseline to Week 12. Secondary outcomes Change in Beck Depression Inventory-II (BDI-II) score from baseline to Week 12. Change in Perceived Stress Scale (PSS-10) score from baseline to Week 12. Changes in gut microbiome composition and diversity (α-diversity, β-diversity and relative abundance of bacterial taxa) between baseline and Week 12. Safety and tolerability of probiotic supplementation, assessed by adverse events and treatment discontinuation. Intervention: OmniBiotic Stress Repair Microbiome Analysis Subgroup Stool samples will be collected at: * Baseline * 1 month * 3 months Analysis will follow methodologies similar to Mörkl S et al. (2025). Remark: Additional sampling at 1 week (as done in the referenced study) is considered unnecessary, as it falls outside routine clinical monitoring. Antidepressant Strategy * Include patients receiving SSRI (Selective Serotonin Reuptake Inhibitors) and possibly SNRI (Serotonin-Norepinephrine Reuptake Inhibitors) * Advantage: broader applicability * Limitation: increased variability

Participants needed: 200
Trial details
Age: 18-65Biological sex: AllType: InterventionalSponsor: University MariborUpdated: Aug 31, 2026Locations: 1
Eligibility criteria

Confirmed diagnosis of depression according to ICD 11 (International Classificat... [+2]

- Acute suicidality [+8]

Status: Not yet recruiting

Effects of Kefir on Celiac Disease

This study will investigate whether regular consumption of kefir can reduce gastrointestinal symptoms and improve quality of life in adults with celiac disease who follow a strict gluten-free diet. The study will use a randomized cross-over design in which participants will consume kefir during one study period and continue their usual diet without kefir during another period.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University MariborUpdated: Aug 20, 2026Locations: 1
Eligibility criteria

Adults aged 18 years or older with a confirmed diagnosis of celiac disease. [+1]

Other chronic gastrointestinal diseases. [+2]

Status: Recruiting

Effect of Probiotics After Neurosurgery

The goal of this randomised controlled trial is to determine the effect of consuming a multistrain probiotic OMNi-BiOTiC® Hetox on improving the healing, pain management, and postsurgical complications after neurosurgery. The main question it aims to answer is: • Is the multistrain probiotic OMNi-BiOTiC® Hetox effective in in improving patient-reported disability after neurosurgery? Researchers will compare the probiotic group and the placebo group to determine if the healing is significantly different between the groups.

Participants needed: 110
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: University MariborUpdated: Nov 28, 2025Locations: 1
Eligibility criteria

adults with MRI-confirmed disc herniation, stenosis, or instability of the lumba... [+3]

symptoms of acute infection (vomiting, fever above 38°C, diarrhea, respiratory s... [+2]

Status: Recruiting

Probiotics for Diaper Dermatitis

The goal of this randomized controlled clinical trial is to determine the effect of the probiotic OMNiBiOTiC® Panda in treating diaper dermatitis in children under the age of two years. The main question it aims to answer is: Is the probiotic OMNiBiOTiC® Panda effective in reducing the duration of diaper dermatitis in children under the age of two years? Researchers will compare the probiotic and placebo group to see if the duration of diaper dermatitis is significant among the two groups. Participants will: * receive 6 droplets daily of probiotic or placebo for 3 weeks and * observe and record improvement of diaper rash symptoms each day using a diary.

Participants needed: 42
Trial details
Age: 1-2Biological sex: AllType: InterventionalSponsor: University MariborUpdated: Nov 24, 2025Locations: 1
Eligibility criteria

presence of diaper dermatitis [+1]

previous use of probiotics [+4]